Canadian Biopharmaceutical Company Developing Covid-19 Treatment
Edesa Biotech is a Canadian biopharmaceutical company and has just announced that they have received approval from Health Canada to begin a Phase 2/3 clinical study of their experimental drug, EB05, being developed as a potential treatment for Covid-19. Edesa Biotech is now seeking government grants to help expediate the process of the study.
EB05 is an antibody with the ability to suppress the body releasing inflammatory cytokines seen in severe coronavirus cases. To get a bit more technical, EB05, “inhibits toll-like receptor 4 (TLR4) signaling”, which is important to our immune systems and mediates the inflammation we see causing acute lung injury commonly seen with coronavirus patients.
Edesa’s Phase 2/3 study will be an, “Adaptive, multicenter, randomized, double-blind, placebo-controlled” study. This will allow the company to evaluate how effective and safe the drug is with hospitalized patients with moderate to severe COVID-19. The study is planned to have about 355 patients in the first phase. The patients will have either the drug or a placebo administered via IV. If the test goes well, there will be a phase 3.
Dr. Par Nijhawan, the CEO of Edesa Biotech, said “We greatly appreciate the actions being taken by the government to expedite COVID-19 applications and provide support for clinical studies.”
This is a developing story that we are following closely, for more updates be sure to check back with the ABN blog regularly.